Allist(SH:688578) Cai Jing Wang·2025-10-29 04:37Core Insights - The company reported a significant increase in revenue and net profit for the first three quarters of 2025, with total revenue reaching 3.733 billion yuan, a year-on-year increase of 47.4%, and net profit attributable to shareholders at 1.616 billion yuan, up 52.01% [1] - The third quarter alone saw revenue of 1.359 billion yuan, reflecting a 42.03% year-on-year growth, and a net profit of 565 million yuan, which is a 38.77% increase compared to the same period last year [1] Revenue and Profit Growth - For the first three quarters, the company's operating income was 3.733 billion yuan, with a year-on-year growth of 47.4% [1] - The net profit attributable to shareholders for the same period was 1.616 billion yuan, marking a 52.01% increase [1] - The adjusted net profit, excluding non-recurring items, was 1.45 billion yuan, showing a year-on-year rise of 43.6% [1] Product Performance - The sales revenue of Fumetinin tablets has steadily increased, enhancing the accessibility of medication for patients and expanding the beneficiary group of lung cancer patients [1] - The marketing team is actively promoting the synergistic effects of the commercialized product RET inhibitor, Pralsetinib capsules, alongside Fumetinin [1] - The RET inhibitor Pralsetinib has transitioned from overseas production to domestic manufacturing for market launch [1]